We have been exploring novel avenues for effectively and safely treating Alzheimer's and other beta-amyloidopathy disease patients. We believe AmyTrap-3, our flagship therapeutic, will address this unmet medical need. We also envision our technology making a significant clinical impact on other neurodegenerative diseases.
Our mission is to effectively alleviate beta-amyloidopathy symptoms without subjecting patients to pain and suffering. Our passion is to improve the quality of life in patients by bringing our proof-of-concept tested and pre-clinically validated beta-amyloid capturing molecules into the clinic.